Compare · INDV vs NVO
INDV vs NVO
Side-by-side comparison of Indivior Pharmaceuticals Inc. (INDV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INDV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 44.1x INDV ($5.06B).
- Over the past year, INDV is up 153.1% and NVO is down 21.8% - INDV leads by 174.9 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for INDV).
- NVO has more recent analyst coverage (25 ratings vs 7 for INDV).
- Company
- Indivior Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $40.54-0.07%
- $50.31-2.25%
- Market cap
- $5.06B
- $222.81B
- 1M return
- +6.59%
- +15.47%
- 1Y return
- +153.14%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 5
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INDV
- Chief Scientific Officer Heidbreder Christian sold $764,628 worth of shares (18,586 units at $41.14) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 209,337 units (SEC Form 4)
- Chief Executive Officer Ciaffoni Joseph converted options into 1,266,903 shares and covered exercise/tax liability with 612,549 shares, increasing direct ownership by 481% to 790,330 units (SEC Form 4) to cover taxes
- Barclays initiated coverage on Indivior with a new price target
- Chief Scientific Officer Heidbreder Christian sold $707,383 worth of shares (18,586 units at $38.06) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 227,923 units (SEC Form 4)
- Chief Financial Officer Preblick Ryan sold $1,357,200 worth of shares (36,000 units at $37.70) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 284,751 units (SEC Form 4)
- New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)
- Director Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)
- Director Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S